文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关急性呼吸窘迫综合征患者的纵向呼吸亚表型:三项观察性队列研究结果

Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts.
PubMed 文献 · Lancet Respir Med · 2021-10-13
一句话结论COVID-19相关ARDS基线时无一致呼吸亚表型,但通气比和机械功率的上升轨迹可独立预测28天死亡率(通气比OR 1.64,机械功率OR 1.82)。

本研究基于荷兰22个ICU的前瞻性观察队列PRoVENT-COVID(衍生队列1007例)及美国两个ICU的复现队列(288例和326例),采用潜在类别分析和基于组的轨迹建模识别COVID-19相关ARDS的呼吸亚表型。横断面潜在类别分析未识别出任何亚表型;纵向分析识别出两种亚表型,亚表型2以更高的机械功率、分钟通气量和通气比为特征,28天死亡率无显著差异(32% vs 28%,p=0.10),但无呼吸机天数更少(中位0天 vs 5天,p=0.016)且静脉血栓事件更频繁(32% vs 26%,p=0.048)。轨迹建模显示通气比和机械功率的上升轨迹是28天死亡率的独立预测因素(通气比OR 1.64,95%CI 1.17-2.29;机械功率OR 1.82,95%CI 1.24-2.66),通气比上升轨迹与28天死亡率的关联在两个复现队列中得到证实(复现队列1 OR 4.65,95%CI 1.87-11.6;复现队列2 OR 1.89,95%CI 1.05-3.37)。

要点

  • COVID-19相关ARDS在基线时无一致呼吸亚表型,横断面潜在类别分析未识别出任何亚表型。
  • 纵向分析识别出两种亚表型:亚表型2机械功率、分钟通气量和通气比更高,但PaO2/FiO2、pH和呼吸系统顺应性无差异。
  • 亚表型2 vs 亚表型1:28天死亡率32% vs 28%(p=0.10,无显著差异),无呼吸机天数中位0天 vs 5天(p=0.016),静脉血栓事件32% vs 26%(p=0.048)。
  • 通气比上升轨迹与28天死亡率独立相关(OR 1.64,95%CI 1.17-2.29),机械功率上升轨迹OR 1.82(95%CI 1.24-2.66)。
  • 通气比上升轨迹与28天死亡率的关联在复现队列1(OR 4.65,95%CI 1.87-11.6)和复现队列2(OR 1.89,95%CI 1.05-3.37)中得到证实。

适用人群与场景

  • 荷兰22个ICU连续纳入的接受有创机械通气的COVID-19患者(年龄18岁或以上,RT-PCR确诊),作为衍生队列。
  • 美国两个ICU的类似患者作为复现队列(复现队列1共288例,复现队列2共326例)。

研究设计与关键结果

  • PRoVENT-COVID为研究者发起的全国性多中心前瞻性观察队列研究,2020年3月1日至5月15日荷兰22个ICU共1007例患者纳入衍生队列,复现队列1共288例、复现队列2共326例。
  • 横断面潜在类别分析未识别出任何潜在亚表型;纵向潜在类别分析(使用有创通气前4天每8小时数据)识别出两种不同亚表型。
  • 亚表型2特征为有创机械通气前4天机械功率、分钟通气量和通气比高于亚表型1,但PaO2/FiO2、pH和呼吸系统顺应性在两种亚表型间无差异。
  • 亚表型1共671例中185例(28%)死亡,亚表型2共336例中109例(32%)死亡(p=0.10,无显著差异)。
  • 亚表型2 vs 亚表型1:28天无呼吸机天数中位0天(IQR 0-15)vs 5天(IQR 0-17),p=0.016;静脉血栓事件109/336例(32%)vs 176/671例(26%),p=0.048。
  • 基于组的轨迹建模显示通气比和机械功率的轨迹与潜在类别分析所得亚表型轨迹动态相似:轨迹A为有创通气前4天数值稳定,轨迹B为上升轨迹。
  • 上升轨迹为28天死亡率的更好独立预测因素:通气比OR 1.64(95%CI 1.17-2.29),机械功率OR 1.82(95%CI 1.24-2.66)。
  • 通气比上升轨迹(轨迹B)与28天死亡率的关联在复现队列中得到证实:复现队列1 OR 4.65(95%CI 1.87-11.6),复现队列2 OR 1.89(95%CI 1.05-3.37)。

证据类型、等级与局限

  • 证据类型:研究者发起的全国性多中心前瞻性观察队列研究(PRoVENT-COVID,ClinicalTrials.gov NCT04346342),并有美国两个ICU的复现队列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19相关ARDS患者从相对均质人群分化为更具异质性的人群,通气比和机械功率的轨迹最具区分度;仅对这些参数建模即可为机械通气时长和死亡率提供预后价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with COVID-19-related acute respiratory distress syndrome (ARDS) have been postulated to present with distinct respiratory subphenotypes. However, most phenotyping schema have been limited by sample size, disregard for temporal dynamics, and insufficient validation. We aimed to identify respiratory subphenotypes of COVID-19-related ARDS using unbiased data-driven approaches.

METHODS: PRoVENT-COVID was an investigator-initiated, national, multicentre, prospective, observational cohort study at 22 intensive care units (ICUs) in the Netherlands. Consecutive patients who had received invasive mechanical ventilation for COVID-19 (aged 18 years or older) served as the derivation cohort, and similar patients from two ICUs in the USA served as the replication cohorts. COVID-19 was confirmed by positive RT-PCR. We used latent class analysis to identify subphenotypes using clinically available respiratory data cross-sectionally at baseline, and longitudinally using 8-hourly data from the first 4 days of invasive ventilation. We used group-based trajectory modelling to evaluate trajectories of individual variables and to facilitate potential clinical translation. The PRoVENT-COVID study is registered with ClinicalTrials.gov, NCT04346342.

FINDINGS: Between March 1, 2020, and May 15, 2020, 1007 patients were admitted to participating ICUs in the Netherlands, and included in the derivation cohort. Data for 288 patients were included in replication cohort 1 and 326 in replication cohort 2. Cross-sectional latent class analysis did not identify any underlying subphenotypes. Longitudinal latent class analysis identified two distinct subphenotypes. Subphenotype 2 was characterised by higher mechanical power, minute ventilation, and ventilatory ratio over the first 4 days of invasive mechanical ventilation than subphenotype 1, but PaO2/FiO2, pH, and compliance of the respiratory system did not differ between the two subphenotypes. 185 (28%) of 671 patients with subphenotype 1 and 109 (32%) of 336 patients with subphenotype 2 had died at day 28 (p=0·10). However, patients with subphenotype 2 had fewer ventilator-free days at day 28 (median 0, IQR 0-15 vs 5, 0-17; p=0·016) and more frequent venous thrombotic events (109 [32%] of 336 patients vs 176 [26%] of 671 patients; p=0·048) compared with subphenotype 1. Group-based trajectory modelling revealed trajectories of ventilatory ratio and mechanical power with similar dynamics to those observed in latent class analysis-derived trajectory subphenotypes. The two trajectories were: a stable value for ventilatory ratio or mechanical power over the first 4 days of invasive mechanical ventilation (trajectory A) or an upward trajectory (trajectory B). However, upward trajectories were better independent prognosticators for 28-day mortality (OR 1·64, 95% CI 1·17-2·29 for ventilatory ratio; 1·82, 1·24-2·66 for mechanical power). The association between upward ventilatory ratio trajectories (trajectory B) and 28-day mortality was confirmed in the replication cohorts (OR 4·65, 95% CI 1·87-11·6 for ventilatory ratio in replication cohort 1; 1·89, 1·05-3·37 for ventilatory ratio in replication cohort 2).

INTERPRETATION: At baseline, COVID-19-related ARDS has no consistent respiratory subphenotype. Patients diverged from a fairly homogenous to a more heterogeneous population, with trajectories of ventilatory ratio and mechanical power being the most discriminatory. Modelling these parameters alone provided prognostic value for duration of mechanical ventilation and mortality.

FUNDING: Amsterdam UMC.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Bos LDJ, Sjoding M, Sinha P, et al. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respir Med. 2021. PMID: 34653374. doi:10.1016/S2213-2600(21)00365-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。